• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Retention of opioid agonist treatment prescribers across New South Wales, Australia, 2001-2018: Implications for treatment systems and potential impact on client outcomes.澳大利亚新南威尔士州 2001-2018 年阿片类激动剂治疗处方医生保留情况:对治疗系统的影响及对患者结局的潜在影响。
Drug Alcohol Depend. 2021 Feb 1;219:108464. doi: 10.1016/j.drugalcdep.2020.108464. Epub 2020 Dec 19.
2
The effect of person, treatment and prescriber characteristics on retention in opioid agonist treatment: a 15-year retrospective cohort study.患者、治疗和处方医生特征对阿片类激动剂治疗保留率的影响:一项长达 15 年的回顾性队列研究。
Addiction. 2021 Nov;116(11):3139-3152. doi: 10.1111/add.15514. Epub 2021 May 12.
3
Does opioid agonist treatment reduce overdose mortality risk in people who are older or have physical comorbidities? Cohort study using linked administrative health data in New South Wales, Australia, 2002-17.阿片类激动剂治疗是否降低老年或合并躯体疾病人群的过量死亡风险?澳大利亚新南威尔士州 2002-17 年基于行政健康数据的队列研究。
Addiction. 2023 Aug;118(8):1527-1539. doi: 10.1111/add.16178. Epub 2023 Mar 20.
4
Prescribing practices in opioid agonist treatment and changes in compliance to clinical dosing guidelines in British Columbia, Canada.在加拿大不列颠哥伦比亚省,阿片类激动剂治疗中的处方实践和对临床剂量指南的遵从性变化。
Addiction. 2024 Aug;119(8):1453-1459. doi: 10.1111/add.16491. Epub 2024 Apr 7.
5
The real-world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine.在乌克兰,美沙酮和丁丙诺啡维持治疗的实际影响。
Addiction. 2021 Jan;116(1):83-93. doi: 10.1111/add.15115. Epub 2020 Aug 9.
6
Trends in use of medicines for opioid agonist treatment in Australia, 2013-2022.澳大利亚 2013-2022 年阿片类激动剂治疗药物使用趋势。
Int J Drug Policy. 2024 Jan;123:104255. doi: 10.1016/j.drugpo.2023.104255. Epub 2023 Nov 28.
7
Reductions in emergency department presentations associated with opioid agonist treatment vary by geographic location: A retrospective study in New South Wales, Australia.阿片类激动剂治疗与急诊科就诊人次减少相关,其变化与地理位置有关:来自澳大利亚新南威尔士州的一项回顾性研究。
Drug Alcohol Rev. 2019 Sep;38(6):690-698. doi: 10.1111/dar.12976.
8
A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia.澳大利亚新南威尔士州美沙酮和丁丙诺啡维持治疗阿片类药物依赖的纵向比较。
Addiction. 2015 Apr;110(4):646-55. doi: 10.1111/add.12834.
9
Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.澳大利亚注射吸毒者阿片类激动剂治疗中断的发生率及相关因素。
Addiction. 2021 Mar;116(3):525-535. doi: 10.1111/add.15168. Epub 2020 Jul 14.
10
Inability to contact opioid agonist therapy prescribers during the COVID-19 pandemic in a Canadian setting: a cross-sectional analysis among people on opioid agonist therapy.在加拿大,COVID-19 大流行期间无法联系阿片类激动剂治疗医生:阿片类激动剂治疗者中的横断面分析。
Addict Sci Clin Pract. 2022 Dec 15;17(1):73. doi: 10.1186/s13722-022-00354-x.

引用本文的文献

1
Primary care physician characteristics associated with becoming opioid agonist treatment prescribers in British Columbia: a retrospective case-control study.不列颠哥伦比亚省与成为阿片类激动剂治疗处方医生相关的基层医疗医生特征:一项回顾性病例对照研究。
Harm Reduct J. 2025 Jun 25;22(1):111. doi: 10.1186/s12954-025-01261-5.
2
Identifying opioid agonist treatment prescriber networks from health administrative data: A validation study.从卫生行政数据中识别阿片类激动剂治疗处方医生网络:一项验证研究。
PLoS One. 2025 May 16;20(5):e0322064. doi: 10.1371/journal.pone.0322064. eCollection 2025.
3
Data Resource Profile Update: The Opioid Agonist Treatment and Safety II (OATS II) Study, 2001-22, New South Wales, Australia.数据资源概况更新:2001 - 2022年澳大利亚新南威尔士州阿片类激动剂治疗与安全性II(OATS II)研究
Int J Epidemiol. 2025 Feb 16;54(2). doi: 10.1093/ije/dyaf037.
4
Practical solutions to resolve social barriers to hepatitis C treatment initiation among people who inject drugs: a qualitative study.解决注射吸毒者中丙型肝炎治疗起始社会障碍的实用解决方案:一项定性研究
Harm Reduct J. 2024 Dec 20;21(1):221. doi: 10.1186/s12954-024-01136-1.
5
Exploring a pilot alcohol and other drug (AOD) nurse practitioner mentoring program: Empirical research mixed methods: A pilot nurse practitioner mentoring program.探索试点酒精和其他药物(AOD)护士从业者指导计划:实证研究混合方法:试点护士从业者指导计划。
Nurs Open. 2024 Aug;11(8):e2250. doi: 10.1002/nop2.2250.
6
Opioid prescribing patterns among medical practitioners in New South Wales, Australia.澳大利亚新南威尔士州医务人员的阿片类药物处方模式。
Drug Alcohol Rev. 2023 Sep;42(6):1472-1481. doi: 10.1111/dar.13675. Epub 2023 May 9.
7
Challenges of methadone maintenance treatment decentralisation from Vietnamese primary care providers' perspectives.从越南基层医疗服务提供者的视角看美沙酮维持治疗去中心化面临的挑战。
Drug Alcohol Rev. 2023 May;42(4):803-814. doi: 10.1111/dar.13613. Epub 2023 Feb 27.

本文引用的文献

1
Risk of discharge against medical advice among hospital inpatients with a history of opioid agonist therapy in New South Wales, Australia: A cohort study and nested crossover-cohort analysis.澳大利亚新南威尔士州有阿片类激动剂治疗史的住院患者出院时不遵医嘱的风险:一项队列研究和嵌套交叉队列分析。
Drug Alcohol Depend. 2020 Dec 1;217:108343. doi: 10.1016/j.drugalcdep.2020.108343. Epub 2020 Oct 12.
2
Data Resource Profile: The Opioid Agonist Treatment and Safety (OATS) Study, New South Wales, Australia.数据资源简介:澳大利亚新南威尔士州阿片类激动剂治疗与安全性(OATS)研究
Int J Epidemiol. 2021 Jan 23;49(6):1774-1775. doi: 10.1093/ije/dyaa125.
3
DATA 2000 waiver training for medical students: Lessons learned from a medical school experience.医学生 DATA2000 弃权培训:从医学院校经验中获得的教训。
Subst Abus. 2020;41(4):463-467. doi: 10.1080/08897077.2019.1692323. Epub 2020 Feb 7.
4
Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia.澳大利亚经常使用阿片类药物的人群对用于治疗阿片类药物使用障碍的丁丙诺啡延长释放注射剂的看法。
Addiction. 2020 Jul;115(7):1295-1305. doi: 10.1111/add.14941. Epub 2020 Feb 5.
5
Global patterns of opioid use and dependence: harms to populations, interventions, and future action.全球阿片类药物使用和依赖模式:对人群的危害、干预措施和未来行动。
Lancet. 2019 Oct 26;394(10208):1560-1579. doi: 10.1016/S0140-6736(19)32229-9. Epub 2019 Oct 23.
6
Reductions in emergency department presentations associated with opioid agonist treatment vary by geographic location: A retrospective study in New South Wales, Australia.阿片类激动剂治疗与急诊科就诊人次减少相关,其变化与地理位置有关:来自澳大利亚新南威尔士州的一项回顾性研究。
Drug Alcohol Rev. 2019 Sep;38(6):690-698. doi: 10.1111/dar.12976.
7
Using routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) Study.利用常规收集的数据了解和预测阿片类激动剂治疗中的不良结局:阿片类激动剂治疗安全性(OATS)研究方案。
BMJ Open. 2018 Aug 5;8(8):e025204. doi: 10.1136/bmjopen-2018-025204.
8
Associations between pharmacotherapy for opioid dependence and clinical and criminal justice outcomes among adults with co-occurring serious mental illness.同时患有严重精神疾病的成年人中,阿片类药物依赖的药物治疗与临床和刑事司法结局之间的关联。
J Subst Abuse Treat. 2018 Mar;86:17-25. doi: 10.1016/j.jsat.2017.12.003. Epub 2017 Dec 12.
9
Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis.针具和注射器方案以及阿片类药物替代疗法预防注射吸毒人群中 HCV 传播的效果:一项 Cochrane 综述和荟萃分析的结果。
Addiction. 2018 Mar;113(3):545-563. doi: 10.1111/add.14012. Epub 2017 Oct 23.
10
Primary Care Physicians' Views about Prescribing Methadone to Treat Opioid Use Disorder.基层医疗医生对开具美沙酮治疗阿片类物质使用障碍的看法。
Subst Use Misuse. 2018 Jan 28;53(2):344-353. doi: 10.1080/10826084.2017.1325376. Epub 2017 Aug 30.

澳大利亚新南威尔士州 2001-2018 年阿片类激动剂治疗处方医生保留情况:对治疗系统的影响及对患者结局的潜在影响。

Retention of opioid agonist treatment prescribers across New South Wales, Australia, 2001-2018: Implications for treatment systems and potential impact on client outcomes.

机构信息

National Drug and Alcohol Research Centre, University of NSW, Sydney NSW 2052, Australia.

Monash Addiction Research Centre and Eastern Health Clinical School, Monash University, Melbourne, Australia.

出版信息

Drug Alcohol Depend. 2021 Feb 1;219:108464. doi: 10.1016/j.drugalcdep.2020.108464. Epub 2020 Dec 19.

DOI:10.1016/j.drugalcdep.2020.108464
PMID:33360851
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7855715/
Abstract

BACKGROUND

There has been much research on the efficacy and effectiveness of opioid agonist treatment (OAT), but less on its implementation and sustainability. A challenge internationally has been recruiting and retaining prescribers. This paper aims to characterise the prescribers in terms of OAT prescribing behaviours.

METHODS

Retrospective cohort study in New South Wales, Australia. Participants were 2199 OAT prescribers between 1 st August 2001-19th September 2018.We examined trends in initiation and cessation of OAT prescribers. Adjusted hazard ratios were calculated to estimate prescriber retention, adjusting for year of initiation, practice type, client load and treatment prescribed.

RESULTS

The rate of prescribers ceasing OAT prescribing has been increasing over time: a prescriber who initiated between 2016-2017 had over four times the risk of cessation compared with one who initiated before 2001, AHR: 4.77; [3.67-6.21]. The highest prescriber cessation rate was in prescribers who had prescribed for shorter time periods. The annual percentage of prescribers who ceased prescribing among those who prescribed for ≤5 years increased from 3% in 2001 to 20 % in 2017. By 2017 more prescribers were discontinuing prescribing than new prescribers were starting. Approximately 87 % (n = 25,167) of OAT clients were under the care of 20 % of OAT prescribers (n = 202); half had been prescribing OAT for 17+ years.

CONCLUSIONS

OAT prescribing is increasingly concentrated in a small group of mature prescribers, and new prescribers are not being retained. There is a need to identify and respond to the reasons that contribute to newer prescribers to cease prescribing and put in place strategies to increase retention and broaden the base of doctors involved in such prescribing.

摘要

背景

已有大量研究探讨了阿片类激动剂治疗(OAT)的疗效和有效性,但对其实施和可持续性的研究较少。国际上的一个挑战是招募和留住开处方者。本文旨在从 OAT 处方行为的角度描述这些开处方者。

方法

这是澳大利亚新南威尔士州的一项回顾性队列研究。参与者为 2001 年 8 月 1 日至 2018 年 9 月 19 日期间的 2199 名 OAT 开处方者。我们研究了 OAT 开处方者开始和停止的趋势。调整后的危险比用于估计开处方者保留率,调整了起始年份、实践类型、患者量和所开处方的治疗药物。

结果

OAT 处方的开处方者停止开处方的比例随着时间的推移一直在增加:与 2001 年前开始的开处方者相比,2016-2017 年开始的开处方者停止开处方的风险高出四倍以上,调整后的危险比为 4.77;[3.67-6.21]。开处方时间较短的开处方者的处方终止率最高。在开处方时间≤5 年的开处方者中,每年停止开处方的比例从 2001 年的 3%增加到 2017 年的 20%。到 2017 年,停止开处方的开处方者多于开始开处方的新开处方者。大约 87%(n=25167)的 OAT 患者由 20%的 OAT 开处方者(n=202)照顾;其中一半的人已经开 OAT 处方 17 年以上。

结论

OAT 处方越来越集中在一小部分成熟的开处方者手中,而新的开处方者则无法保留。需要确定并应对导致新的开处方者停止开处方的原因,并制定增加保留率和扩大参与此类处方的医生基础的策略。